Koya Medical is committed to transforming venous and lymphatic care. We are actively developing clinical evidence and partnering with leading clinicians, researchers, and institutions around the world as we continue to bring innovations to this space.
Stanley G Rockson, Pat W. Whitworth, Andrea Cooper, Sarah Kania, Heidi Karnofel, Michelle Nguyen, Kristin Shadduck, Phyllis Gingerich, Jane Armer Original Article published in Lymphat Res Biol. 2021 https://doi.org/10.1089/lrb.2020.0126
Jane Wigg, Elizabeth Campione, Anand Doraiswamy, and Stanley G. Rockson, Original article presented at: International Lymphodema Framework (ILF) Conference. 2021. Copenhagen, Denmark and Journal of Wound Care. 2022
Stanley G Rockson, Pat W. Whitworth, Andrea Cooper, Sarah Kania, Heidi Karnofel, Michelle Nguyen, Kristin Shadduck, Phyllis Gingerich, Jane Armer, Journal of Vascular Surgery. 2022 https://doi.org/10.1016/j.jvsv.2022.06.016
Dung Nguyen, Peter Deptula, Halley Darrach, Victoria Posternak, Hui He Stanford Medicine Symposia
Stanley G. Rockson, Pinar Karaca-Mandic, Michelle Nguyen, Kristin Shadduck, Phyllis Gingerich, Elizabeth Campione, and Heather Hettrick Scientific Reports, Nature. 2022 https://doi.org/10.1038/s41598-022-17225-9
Jane Wigg, Elizabeth Campione, Andy Doraiswamy, and Stanley G. Rockson. American Venous and Lymphatic Society. 2022
John Pamplin, Jarren Baldwin, Julia Rodrick, and Anand Doraiswamy Shap. Mem. Superelasticity. ASM International. 2022. https://doi.org/10.1007/s40830-022-00379-w
Jennifer Sibley, Jarren Baldwin, John Pamplin, Julia Rodrick, Charles Liu, Heather Hettrick, and Anand Doraiswamy Biomedical Materials & Devices (2023). https://link.springer.com/article/10.1007/s44174-023-00070-3
The study met its primary and secondary endpoints
• Reduction in limb volume: 369.9 ± 68.19 mL vs. 83.1 ± 67.99 mL, P<0.05* (subjects on Dayspring treatment removed greater than 4 times the fluid compared to when they were on the APCD treatment)
• Improvement in overall Quality of Life (LYMQOL): 1.01 ± 0.23 vs. 0.17 ± 0.18, P<0.05*,
• Treatment adherence: 81% vs. 56%, P<0.001*
* indicates statistical significance. Barfield, Michael et al. Journal of Vascular Surgery: Venous and Lymphatic Disorders. Volume 0, Issue 0, 101965. https://doi.org/10.1016/j.jvsv.2024.101965
Lipedema and lymphedema remain misunderstood and underappreciated diseases. While the conditions appear similar, each presents with unique pathophysiology. In consideration of this, a novel ambulatory Non-Pneumatic Compression Device (NPCD) was utilized in this study to support lymphatic flow and improve tissue health while permitting and enabling movement.
Wright T, Scarfino C, Baldwin J, Barnhart H, Doraiswamy A, et al. (2023). Ann Case Report 08: 1564. https://doi.org/10.29011/2574-7754.101564.
This study highlights the potential benefits of wearable NPCD treatment for patients managing their condition independently. The approach integrates treatment into daily routines, potentially improving long-term adherence to therapy for breast cancer-related lymphedema (BCRL). By focusing on practical functionality, NPCD allows patients to maintain mobility and engage in necessary exercises during treatment, representing a significant advancement in lymphedema management.
Rodrick, J., Barnhart, H., Rockson, S.G. et al. Biomedical Materials & Devices (2024). https://doi.org/10.1007/s44174-024-00201-4
A recently completed clinical trial compared a novel nonpneumatic compression device (NPCD) with a traditional advanced pneumatic compression device (APCD) for the treatment of breast cancer-related lymphedema (BCRL). This subanalysis examines these results within the subset of trial subjects aged ≥ 65 years.
Edema reduction, Quality of Life, and Adherence were significantly greater during NPCD use vs APCD use.
Stanley G. Rockson, MD and Roman Skoracki, MD. Lymphatic Research and Biology. Volume 21, Number 6. 2023. DOI: 10.1089/lrb.2022.0085
This study shows that the Dayspring non-pneumatic compression device (NPCD) results in significant reduction in edema in the foot and ankle, by volume and girth, as well as improvement in Quality of Life (QOL).
Rao A, Berland T, Mullick A, Maldonado TS, Blumberg SN. Vascular. 2024;0(0). doi:10.1177/17085381241305898
Novel self‑care solutions that are more convenient and that interfere less with daily activities couldincrease self‑care adherence and ultimately reduce complication‑related costs of BCRL.
Karaca‑Mandic et al. Cost Effectiveness and Resource Allocation (2023) 21:47 https://doi.org/10.1186/s12962‑023‑00455‑7
Innovations in compression therapy such as the Dayspring device may prove useful in this at-risk patient population, with benefits including fewer amputations and medical transfers, lower wound recidivism, and higher treatment completion rates.
https://podiatrym.com/Clinical_Innovations2.cfm?id=3103
Using a nonpneumatic compression device that combines multiple treatment modalities demonstrates improved efficacy, quality of life, and patient adherence.
Heather Barnhart, PhD; Thomas Maldonado, MD; and Stanley G. Rockson, MD. ADV SKIN WOUND CARE 2024;37:212–5. DOI: 10.1097/ASW.0000000000000091
This commentary is a call to action to embrace innovation to better manage lymphedema and expand educational opportunities by leveraging technology to properly train healthcare providers to manage this disease.
Barnhart, H. Lymphatics 2023, 1, 257–261. https://doi.org/10.3390/ lymphatics1030016
This article will highlight the significance of the venous pump and review the functional anatomy and physiology of the foot and calf, integrating the connection to venous and lymphatic health.
Barnhart, H. Lymphatics 2024, 2, 43–49. https://doi.org/10.3390/ lymphatics2020004
Get in touch to learn more or schedule a virtual or in-person demonstration.
